Perhaps the most significant development in the pharmaceutical industry in decades, crops of biosimilars are being approved and are ready for distribution. What lies next, in terms of legislation and the impact on pharmacists, remains to be seen.Before a once-in-a-generation pandemic struck the globe, adalimumab (Humira; AbbVie) was the most profitable drug in the world; […]
